Search

Your search keyword '"Iannitto E"' showing total 303 results
Start Over Author "Iannitto E"
303 results on '"Iannitto E"'

1. Primary Mediastinal B‐cell Lymphoma, a nationwide real‐life retrospective study from Fondazione Italiana Linfomi (FIL)

Author

Iannitto, E., primary, Balzarotti, M., additional, Martelli, M., additional, Zinzani, P., additional, Tucci, A., additional, Di Rocco, A., additional, Cavallo, F., additional, Usai, S. V., additional, Guidetti, A., additional, Ravano, E., additional, Merli, F., additional, Botto, B., additional, Pelosini, M., additional, Tecchio, C., additional, Spina, M., additional, Derenzini, E., additional, Finotto, S., additional, Mola, B., additional, Pinto, A., additional, Zanni, E., additional, Battistini, R., additional, Hohaus, S., additional, Dogliotti, I., additional, Gini, G., additional, Zilioli, V. R., additional, De Lorenzo, S., additional, Dodero, A., additional, Broccoli, A., additional, Maggi, A., additional, Mannarella, C., additional, Chiarenza, A., additional, Pastore, D., additional, Cascavilla, N., additional, Musto, P., additional, Stelitano, C., additional, Di Raimondo, F., additional, Di Renzo, N., additional, Liberati, A. M., additional, Salerno, M., additional, Scalone, R., additional, Nassi, L., additional, Patti, C., additional, Polizzi, V., additional, Guarini, A., additional, Amato, G., additional, Ciccone, G., additional, Evangelista, A., additional, Lo Presti, F., additional, La Porta, A., additional, Mannina, D., additional, Calogero, R. D., additional, Musso, M., additional, and Consoli, U., additional

Published
2023
Full Text
View/download PDF

2. “Real world” outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the “rete ematologica pugliese”

Author

Mele, G., Melpignano, A., Quarta, G., Palumbo, G., Capalbo, S., Falcone, A., Cascavilla, N., Palazzo, G., Mazza, P., Iannitto, E., Curci, P., Rizzi, R., Specchia, G., Rossini, B., Pavone, V., Ria, R., Vacca, A., Buquicchio, C., Tarantini, G., Minoia, C., Guarini, A., Ditonno, P., Polimeno, G., Reddiconto, G., and Di Renzo, N.

Published
2015
Full Text
View/download PDF

4. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications

Author

Bikos, V, Darzentas, N, Hadzidimitriou, A, Davis, Z, Hockley, S, Traverse-Glehen, A, Algara, P, Santoro, A, Gonzalez, D, Mollejo, M, Dagklis, A, Gangemi, F, Bosler, D S, Bourikas, G, Anagnostopoulos, A, Tsaftaris, A, Iannitto, E, Ponzoni, M, Felman, P, Berger, F, Belessi, C, Ghia, P, Papadaki, T, Dogan, A, Degano, M, Matutes, E, Piris, M A, Oscier, D, and Stamatopoulos, K

Published
2012
Full Text
View/download PDF

7. Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis

Author

Florena, A.M., Tripodo, C., Di Bernardo, A., Iannitto, E., Guarnotta, C., Porcasi, R., Ingrao, S., Abbadessa, V., and Franco, V.

Subjects
Thrombocythemia -- Physiological aspects, Thrombocythemia -- Research, Thrombocytosis -- Physiological aspects, Thrombocytosis -- Research, Apoptosis -- Research, Apoptosis -- Physiological aspects, Myelofibrosis -- Physiological aspects, Myelofibrosis -- Research, Bone marrow cells -- Physiological aspects, Bone marrow cells -- Research, Health
Published
2009

8. PROGNOSTIC FACTORS, MANAGEMENT AND OUTCOME OF AN INTERNATIONAL SERIES OF 41 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) AND CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT

Author

Ferreri, A. J.M., primary, Tarantino, V., additional, Cabras, G., additional, Ferrara, F., additional, Zinzani, P. L., additional, Arcaini, L., additional, Castellino, A., additional, Tucci, A., additional, Cocito, F., additional, Davies, A., additional, Salvador Chalup, M. M.B, additional, Cwynarski, K., additional, Nogueira, F. L., additional, Petrucci, L., additional, Muzi, C., additional, Onofrillo, D., additional, Ferrario, A., additional, Ramakrishnan, P., additional, Scalzulli, P. R., additional, Tani, M., additional, Tisi, M. C., additional, Papageorgiou, S. G., additional, Calimeri, T., additional, Angelillo, P., additional, Foppoli, M., additional, Dimou, M., additional, Ponzoni, M., additional, Iannitto, E., additional, and Vassilakopoulos, T. P., additional

Published
2021
Full Text
View/download PDF

14. Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma

Author

FRANCO, Giovanni, GUARNOTTA, Carla, Piccaluga, PP, Boveri, E, GULINO, Alessandro, Fuligni, F, Rigoni, A, Porcasi, R, Buffa, S, Betto, E, FLORENA, Ada Maria, FRANCO, Vito, Iannitto, E, Arcaini, L, Pileri, SA, Pucillo, C, Colombo, MP, Sangaletti, S, TRIPODO, Claudio, Frossi, B, PORCASI, Rossana, Franco, G, Guarnotta, C, Frossi, Piccaluga, PP, Boveri, E, Gulino, A, Fuligni, F, Rigoni, A, Porcasi, R, Buffa, S, Betto, E, Florena, AM, Franco, V, Iannitto, E, Arcaini, L, Pileri, SA, Pucillo, C, Colombo, MP, Sangaletti, S, Tripodo, C, Franco, Giovanni, Guarnotta, Carla, Frossi, Barbara, Piccaluga, Pier Paolo, Boveri, Emanuela, Gulino, Alessandro, Fuligni, Fabio, Rigoni, Alice, Porcasi, Rossana, Buffa, Salvatore, Betto, Elena, Florena, Ada Maria, Franco, Vito, Iannitto, Emilio, Arcaini, Luca, Pileri, Stefano Aldo, Pucillo, Carlo, Colombo, Mario Paolo, Sangaletti, Sabina, and Tripodo, Claudio

Subjects
Male, Pathology, Biochemistry, Mice, Tumor Microenvironment, Mast Cell, Medicine, Mast Cells, Inflammation Mediator, Aged, 80 and over, Mice, Knockout, B-Lymphocytes, Mice, Inbred BALB C, Mesenchymal Stromal Cell, B-Lymphocyte, CD40 Antigen, Cell Differentiation, Hematology, Middle Aged, Prognosis, medicine.anatomical_structure, Disease Progression, Cytokines, Female, Inflammation Mediators, Clone (B-cell biology), Human, Adult, medicine.medical_specialty, Stromal cell, Prognosi, CD40 Ligand, Immunology, Disease-Free Survival, Animals, Humans, Splenic marginal zone lymphoma, CD40 Antigens, Cytokine, B cell, Aged, Cell Proliferation, Animal, business.industry, Mesenchymal stem cell, Mesenchymal Stem Cells, Lymphoma, B-Cell, Marginal Zone, Cell Biology, Genes, p53, medicine.disease, Lymphoma, Splenic marginal zone lymphoma, bone marrow microenvironment, CD40, Mast cell sarcoma, Bone marrow, business
Abstract

Splenic marginal zone lymphoma (SMZL) is a mature B-cell neoplasm characterized by rather indolent clinical course. However, nearly one third of patients experience a rapidly progressive disease with a dismal outcome. Despite the characterization of clone geneticsandthe recognition of deregulated immunologic stimulation in the pathogenesis of SMZL, little is known about microenvironment dynamics and their potential biological influence on disease outcome. Here we investigate the effect of stroma-intrinsic features on SMZL disease progression by focusing on the microenvironment of the bone marrow (BM), which represents an elective disease localization endorsing diagnostic and prognostic relevance. We show that the quality of the BM stromal meshwork of SMZL infiltrates correlates with time to progression. In particular, we describe the unfavorable prognostic influence of dense CD40 expression by BM stromal cells, which involves the contribution of CD40 ligand (CD40L)-expressing bystander mast cells infiltrating SMZL BM aggregates. The CD40/CD40L-assisted crosstalk between mesenchymal stromal cells and mast cells populating the SMZL microenvironment finds correlation in p53-/- mice developing SMZL and contributes to the engendering of detrimental proinflammatory conditions. Our study highlights a dynamic interaction, playing between nonneoplastic elements within the SMZL niche, toward disease progression. © 2014 by The American Society of Hematology.

Published
2014
Full Text
View/download PDF

15. FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY

Author

Ferrero, S., primary, Ladetto, M., additional, Beldjord, K., additional, Drandi, D., additional, Stelitano, C., additional, Bernard, S., additional, Castagnari, B., additional, Bouabdallah, K., additional, Cesaretti, M., additional, Alvarez, I., additional, Gressin, R., additional, Ponzoni, M., additional, Tripodo, C., additional, Traverse-Glehen, A., additional, Baseggio, L., additional, Liberati, A., additional, Merli, M., additional, Tessoulin, B., additional, Patti, C., additional, Cabras, M., additional, Feugier, P., additional, Pozzi, S., additional, Zucca, E., additional, Iannitto, E., additional, and Thieblemont, C., additional

Published
2019
Full Text
View/download PDF

16. PREDICTIVE VALUE OF END-OF-TREATMENT POSITRON EMISSION TOMOGRAPHY SCAN AFTER DA-EPOCH-R IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA. REAL-LIFE EXPERIENCE

Author

Derenzini, E., primary, Ramadan, S., additional, Vanazzi, A., additional, Radice, T., additional, Avenoso, D., additional, Mulè, A., additional, Sammassimo, S., additional, Gigli, F., additional, Iannitto, E., additional, Consoli, U., additional, Patti, C., additional, and Tarella, C., additional

Published
2019
Full Text
View/download PDF

17. Overall survival impact of BEACOPP versus ABVD in advanced hodgkin lymphoma: a pooled analysis of 4 randomized trials

Author

Andre, M., Fortpied, C., Viviani, S., Bellei, M., Carde, P., Hutchings, M., Gianni, A., Brice, P., Casasnovas, O., Gobbi, P., Zinzani, P. L., Dupuis, J., Iannitto, E., Rambaldi, A., Briere, J., Perrot, A., Heczko, M., Valagussa, P., Jonathan Douxfils, Joubert, C., Federico, M., Mounier, N., CHU UCL Namur, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione 'Istituto Neurologico Nazionale C. Mondino', Università degli Studi di Modena e Reggio Emilia (UNIMORE), Institut Gustave Roussy (IGR), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, Service d'hématologie greffe [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hématologie Clinique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Lipides - Nutrition - Cancer (U866) (LNC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bourgogne (UB)-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Service d'Hématologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Research Unit in Environmental and Evolutionary Biology (URBE), Rue de Bruxelles 61, Facultés Universitaires Notre Dame de la Paix (FUNDP), Hôpital Archet 2 [Nice] (CHU), université de Bourgogne, LNC, European Organisation for Research and Treatment of Cancer [Bruxelles] ( EORTC ), European Cancer Organisation [Bruxelles] ( ECCO ), Istituto di Ricovero e Cura a Carattere Scientifico ( IRCCS ), Università di Modena e Reggio Emilia - UNIMORE (Modena, Italy), Institut Gustave Roussy ( IGR ), Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), service hématologie Besançon, CHU, Faculté Universitaire Notre Dame de la Paix ( FUNDP ), and Hôpital Archet 2 [Nice] ( CHU )

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Survival impact, [ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology, ABVD, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hodgkin lymphoma, BEACOPP, Chimiothérapie
Abstract

IF 6.671; International audience

Published
2016

18. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

Author

Ghielmini M., Vitolo U., Kimby E., Montoto S., Walewski J., Pfreundschuh M., Federico M., Hoskin P., McNamara C., Caligaris Cappio F., Stilgenbauer S., Marcus R., Trneny M., Dreger P., Montserrat E., Dreyling M., Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma, Arcaini L., Campo E., Coiffier B., Corradini P., D'Amore F., Gallamini A., Gaulard P., Geisler C. H., Gisselbrecht C., da Silva M. G., Gribben J., Hermine O., Iannitto E., Kim W. S., Kluin Nelemans H. C., Koch P., Ladetto M., Le Gouill S., Lopez Guillermo A., Montalban C., Raderer M., Rodriguez J., Salles G., Bernard C., Schmitz N., Shpilberg O., Thieblemont C., Tilly H., Tournilhac O., Trümper L., Wotherspoon A., Zucca E., AGOSTINELLI, CLAUDIO, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Stem Cell Aging Leukemia and Lymphoma (SALL), Ghielmini M., Vitolo U., Kimby E., Montoto S., Walewski J., Pfreundschuh M., Federico M., Hoskin P., McNamara C., Caligaris-Cappio F., Stilgenbauer S., Marcus R., Trneny M., Dreger P., Montserrat E., Dreyling M., Panel Members of the 1st ESMO Consensus Conference on Malignant Lymphoma, Agostinelli C., Arcaini L., Campo E., Coiffier B., Corradini P., D'Amore F., Gallamini A., Gaulard P., Geisler C.H., Gisselbrecht C., da Silva M.G., Gribben J., Hermine O., Iannitto E., Kim W.S., Kluin-Nelemans H.C., Koch P., Ladetto M., Le Gouill S., Lopez-Guillermo A., Montalban C., Raderer M., Rodriguez J., Salles G., Bernard C., Schmitz N., Shpilberg O., Thieblemont C., Tilly H., Tournilhac O., Trümper L., Wotherspoon A., and Zucca E.

Subjects
Oncology, medicine.medical_specialty, Pathology, Lymphoma, consensus conference, Chronic lymphocytic leukemia, diffuse large B-cell lymphoma, Follicular lymphoma, Disease, Malignant lymphoma, follicular lymphoma, immune system diseases, chronic lymphocytic, leukemia, treatment, Internal medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, medicine, Large B-Cell, Humans, Chronic, Lymphoma, Follicular, Neoplasm Staging, Leukemia, business.industry, Consensus conference, B-Cell, Follicular, Disease Management, Hematology, medicine.disease, Diffuse, Combined Modality Therapy, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocytic, Positron-Emission Tomography, Practice Guidelines as Topic, Mantle cell lymphoma, Lymphoma, Large B-Cell, Diffuse, business, Diffuse large B-cell lymphoma, Stem Cell Transplantation
Abstract

To complete the existing treatment guidelines for all tumor types, ESMO organizes consensus conferences to better clarify open issues in each disease. In this setting, a consensus conference on the management of lymphoma was held on 18 June 2011 in Lugano, immediately after the end of the 11th International Conference on Malignant Lymphoma. The consensus conference convened ∼45 experts from all around Europe and selected six lymphoma entities to be addressed; for each of them three to five open questions were to be discussed by the experts. For each question, a recommendation should be given by the panel, supported by the strength of the recommendation based on the level of evidence. This consensus report focuses on the three most common lymphoproliferative malignancies: diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. A second report will concentrate on mantle cell lymphoma, marginal zone lymphoma and T-cell lymphomas.

Published
2013

19. Viral Sequence Analysis of Occult HBV Infection and Its Reactivation in Immunosuppressed Patients

Author

Donatella Ferraro, Pizzillo, P., Urone, N., Iannitto, E., Craxí, A., Di Stefano, R., Ferraro, D., Pizzillo, P., Urone, N., Iannitto, E., Craxi, A., and DI STEFANO, R.

Subjects
Male, Hepatitis B virus, Settore MED/07 - Microbiologia E Microbiologia Clinica, Settore MED/12 - Gastroenterologia, Genotype, occult HBV, HBV reactivation, phylogenetic analysis,molecular epidemiology, Genetic Variation, Sequence Analysis, DNA, Hepatitis B, Immunocompromised Host, DNA, Viral, Humans, Female, Retrospective Studies
Abstract

Mechanisms associated with reactivation of hepatitis B virus (HBV) in patients with occult HBV infection (OBI) remain unclear. In some cases immunosuppression is an enhancer of viral replication. However, not all patients with OBI who undergo immunosuppression experience reactivation. This study explores the role of viral heterogeneity as a determinant of occult HBV reactivation. HBV genotype, mutation patterns and quasispecies were assessed by sequencing the PreS/S region of 16 patients with OBI undergoing chemotherapy, 3 of whom experienced a OBI reactivation. The latter were also assessed at the time of reactivation. Phylogenetic analysis identified low nucleotide and amino acid diversity rates. There were no differences in the viral quasispecies, or common mutation patterns, detected between patients who underwent reactivation of OBI, and those who did not. Furthermore, upon reactivation, the quasispecies evolved towards a loss of most of the variants present during the initial OBI stage, probably representing the fittest version of the virus. The genetic variability of HBV alone did not account for the transition from occult to overt infection, which appears to be governed principally by the host immune response.

Published
2013

20. Second allogeneic HSCT in patients with acute leukaemia relapsed after a first allogeneic transplantation: a retrospective GITMO study

Author

alida dominietto, Bacigalupo, A., Bruno, B., Zecca, M., Falda, M., Di Bartolomeo, P., Arcese, W., Bosi, A., Fagioli, F., Iannitto, E., Favre, C., Rambaldi, A., Pession, A., Bandini, G., Ciceri, F., Dominietto, A, Bacigalupo, A, Bruno, B, Zecca, M, Falda, M, Di Bartolomeo, P, Arcese, W, Bosi, A, Fagioli, F, Iannitto, E, Favre, C, Rambaldi, A, Pession, A, Bandini, G, and Ciceri, Fabio

Published
2012

21. BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS SALVAGE THERAPY FOR SPLENIC MARGINAL ZONE LYMPHOMA

Author

Iannitto, E, MANCUSO, Salvatrice, Augello, A, FRANCO, Giovanni, Domingo Domenech, E, Pennese, E, Vincenzo, V., Iannitto, E, Mancuso, S, Augello, A, Franco, G, Domingo Domenech, E, Pennese, E, and Vincenzo, V

Subjects
splenic marginal zone lymphoma, bendamustine, Settore MED/15 - Malattie Del Sangue
Abstract

At present, a prospectively validated treatment for SMZL is lacking. Despite this fact, splenectomy is still deemed to be the best choice for patients requiring treatment. Nevertheless, the high fraction of patients achieving a clinical response following splenectomy eventually relapses or progresses

Published
2010

22. A recent update of 3 consecutive prospective trials with high-dose therapy and autograft, without or with rituximab, as primary treatment for advanced-stage follicular lymphoma shows a sizeable group of patients surviving in continuous complete remission

Author

Tarella C, Ladetto M, Benedetti F, Vitolo U, Pulsoni A, Patti C, Callea V, Rambaldi A, Piccin A, Devizzi L, Musso M, Iannitto E, Spedini P, Liberati AM, Gallamini A, Rodeghiero F, Gini G, De Crescenzo A, Di Raimondo F, Levis A, Chisesi T, Petrone T, Scalabrini DR, Rossi G, Carella AM, Parvis G, Majolino I, Passera R, Ruella M, Pileri A, Gianni AM, Corradini P., CICERI , FABIO, Tarella, C, Ladetto, M, Benedetti, F, Vitolo, U, Pulsoni, A, Patti, C, Callea, V, Rambaldi, A, Piccin, A, Devizzi, L, Musso, M, Iannitto, E, Spedini, P, Liberati, Am, Ciceri, Fabio, Gallamini, A, Rodeghiero, F, Gini, G, De Crescenzo, A, Di Raimondo, F, Levis, A, Chisesi, T, Petrone, T, Scalabrini, Dr, Rossi, G, Carella, Am, Parvis, G, Majolino, I, Passera, R, Ruella, M, Pileri, A, Gianni, Am, and Corradini, P.

Published
2010

23. EVALUATING THE RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: IS THE SERUM HEPATITIS B PROFILE RELIABLE?

Author

FERRARO, Donatella, PIZZILLO, Paola, DI MARCO, Vito, CRAXI, Antonio, DI STEFANO, Rosa, VULTAGGIO, A, IANNITTO, E, VENEZIA, G, FERRARO, D, PIZZILLO, P, DI MARCO, V, VULTAGGIO, A, IANNITTO, E, VENEZIA, G, CRAXì, A, and DI STEFANO, R

Subjects
nested PCR, Settore MED/07 - Microbiologia E Microbiologia Clinica, Settore MED/12 - Gastroenterologia, IMMUNOSUPPRESSION, Settore MED/09 - Medicina Interna, HBsAg SEROREVERSION, OBI
Abstract

Background/Aim: Patients with an occult hepatitis B virus (HBV) infection undergoing deep immunosuppression are potentially at risk of HBV reactivation. In order to assess whether a polymerase chain reaction (PCR) assay for HBV DNA in serum could be used to predict the reactivation of an occult HBV infection, we performed a retrospective study in a cohort of Sicilian patients with oncohaematological diseases. Methods: We studied by a highly sensitive ad hoc nested PCR for serum HBV DNA 75 HBsAg-negative oncohaematological patients requiring chemotherapy. Results: Thirty-three patients (44%) were HBV seronegative (anti-HBc and anti-HBs negative) and 42 patients (56%) were HBV seropositive (anti-HBc and/or anti-HBs positive). Baseline serum HBV DNA was positive in nine out of 33 HBV-seronegative patients and in nine out of 42 HBV-seropositive patients (27.3 vs. 21.4%; P=NS). HBsAg seroconversion was observed in five out of 33 seronegative vs. six out of 42 seropositive patients (15 vs. 14%, P=0.9), and in five out of 18 HBV DNA-positive vs. six out of 57 HBV DNA-negative patients (27.7 vs. 10.6%P=0.11). Hepatitis C virus infection was found in 18 patients (24.3%), although with no correlation to HBV serological status, presence of serum HBV DNA or frequency of HBsAg seroconversion. Conclusions: In oncohaematological patients undergoing chemotherapy, highly sensitive serum HBV DNA testing at baseline has a 28% predictive ability to forecast HBsAg seroconversion in HBV DNA-positive patients, and a 90% ability to forecast persistent HBsAg negativity in HBV DNA-negative patients, a better performance than serological tests.

Published
2009

24. Chronic myeloid leukemia as second malignancy; restrospective multicentric study

Author

Iannitto, E, Minardi, V, Barone, R, Cascavilla, N, Caracciolo, C, Di Raimondo, F, Ferrara, F, FRANCO, Giovanni, Liardo, E, Martino, B, Mazza, P, Musolino, C, Musso, M, Musto, P, Pagnucco, G, Palmieri, F, Russo Rossi, A, Specchia, G, Turri, D, Abbadessa, V., MANCUSO, Salvatrice, Iannitto, E, Minardi, V, Barone, R, Cascavilla, N, Caracciolo, C, Di Raimondo, F, Ferrara, F, Franco, G, Liardo, E, Mancuso, S, Martino, B, Mazza, P, Musolino, C, Musso, M, Musto, P, Pagnucco, G, Palmieri, F, Russo Rossi, A, Specchia, G, Turri, D, and Abbadessa, V

Subjects
chronic myeloid leukemia, second malignancy, Settore MED/15 - Malattie Del Sangue
Published
2009

25. Lymphonodal amyloidosis: case report

Author

MANCUSO, Salvatrice, Liardo, E, Augello, A, FRANCO, Giovanni, Iannitto, E, Florena, A., Mancuso, S, Liardo, E, Augello, A, Franco, G, Iannitto, E, and Florena, A

Subjects
Amyloidosis, lymphoma, Settore MED/15 - Malattie Del Sangue
Published
2009

26. 'Final results of a phase II trial of a weekly (W) poly-chemotherapy (CT) with cisplatin (CDDP), epirubicin (EPI), fluorouracil (5FU), folinic acid (FA) and G-CSF for the treatment of gastroesophageal (GE) and gastric (G) cancer (C)'

Author

PALMERI, Laura, DI NOTO, Laura, VAGLICA, Marina, BONGIOVANNI, Alberto, PALMERI, Sergio, Iannitto, E, Palmeri, L, Di Noto, L, Vaglica, M, Bongiovanni, A, Iannitto, E, and Palmeri, S

Subjects
Settore MED/06 - Oncologia Medica, gastric cancer,phase II trial,chemotherapy
Published
2009

27. Chronic myeloid leukemia as second malignancy; a retrospective multicentrico study

Author

Iannitto, E, Minardi, V, Barone, R, Cascavilla, N, Caracciolo, C, Di Raiomondo, F, Ferrara, F, FRANCO, Giovanni, Liardo, E, Martino, B, Mazza, P, Musolino, C, Musso, M, Musto, P, Pagnucco, G, Palmieri, F, Russo Rossi, A, Specchia, G, Turri, D, Abbadessa, V., MANCUSO, Salvatrice, Iannitto, E, Minardi, V, Barone, R, Cascavilla, N, Caracciolo, C, Di Raiomondo, F, Ferrara, F, Franco, G, Liardo, E, Mancuso, S, Martino, B, Mazza, P, Musolino, C, Musso, M, Musto, P, Pagnucco, G, Palmieri, F, Russo Rossi, A, Specchia, G, Turri, D, and Abbadessa, V

Subjects
chronic myeloid leukemia, secondary malignancy, Settore MED/15 - Malattie Del Sangue
Published
2009

28. Bendamustin in association with Rituximab (BR) in the treatment of patients with relapsed/refractory lymphoid neoplasm. A GISL retrospective study

Author

Iannitto, E, Augello, A, Carpaneto, A, Chisesi, T, Di Renzo, N, Ferrara, F, Fizzotti, M, Liardo, E, Madrigali, S, Montanaro, M, Montanini, A, Musso, M, Musto, P, Pennese, E, Rota Scalabrini, D, Scalone, R, Stelitano, C, Abbadessa, V, Federico, M., MANCUSO, Salvatrice, Iannitto, E, Augello, A, Carpaneto, A, Chisesi, T, Di Renzo, N, Ferrara, F, Fizzotti, M, Liardo, E, Madrigali, S, Mancuso, S, Montanaro, M, Montanini, A, Musso, M, Musto, P, Pennese, E, Rota-Scalabrini, D, Scalone, R, Stelitano, C, Abbadessa, V, and Federico, M

Subjects
Lymphoid neoplasms, bendamustin, Settore MED/15 - Malattie Del Sangue
Published
2009

31. Response-based chemotherapy and involved field radiation for intermediate stage Hodgkin disease. A GISL/NHLSG trial

Author

Iannitto, E., Minardi, V., Gobbi, P. G., stefano luminari, Calvaruso, G., Stelitano, C., Baldini, L., Merli, Petrini, M., Marcheselli, L., Mammi, C., Cantis, S., Abbadessa, V., Federico, M., and Iannitto E, Minardi V, Gobbi P, Luminari S, Calvaruso G, Stelitano C, Baldini L, Merli, Petrini M, Marcheselli L,Mammi C, De Cantis S, Abbadessa V, Federico M

Subjects
Hodgkin disease, chemotherapy
Published
2007

33. Splenic marginal zone lymphoma: A prognostic model for clinical use

Author

Arcaini, L, Lazzarino, M, Colombo, N, Burcheri, S, Boveri, E, Paulli, M, Morra, E, Gambacorta, M, Cortelazzo, S, Tucci, A, Ungari, M, Ambrosetti, A, Menestrina, F, Orsucci, L, Novero, D, Pulsoni, A, Frezzato, M, Gaidano, G, Vallisa, D, Minardi, V, Tripodo, C, Callea, V, Baldini, L, Merli, F, Federico, Massimo, Franco, V, Iannitto, E, INTEGRUPPO ITALIANO LINFOMI, Arcaini, L., Lazzarino, M., Colombo, N., Burcheri, S., Boveri, E., Paulli, M., Morra, E., Gambacorta, M., Cortelazzo, S., Tucci, A., Ungari, M., Ambrosetti, A., Menestrina, F., Orsucci, L., Novero, D., Pulsoni, A., Frezzato, M., Gaidano, G., Vallisa, D., Minardi, V., Tripodo, C., Callea, V., Baldini, L., Merli, F., Federico, M., Franco, V., and Iannitto, E.

Subjects
Male, splenic marginal zone lymphoma, prognostic factors, International Prognostic Index (IPI), VILLOUS LYMPHOCYTES, Hydro-Lyase, B-CELL, Longitudinal Studie, Predictive Value of Test, Biochemistry, Gastroenterology, Hemoglobins, chemistry.chemical_compound, International Prognostic Index, Risk Factors, BONE-MARROW INFILTRATION, NON-HODGKINS-LYMPHOMA, C VIRUS-INFECTION, Age Factor, Longitudinal Studies, Multivariate Analysi, Aged, 80 and over, Univariate analysis, Hematology, Mortality rate, Age Factors, Middle Aged, Prognosis, Splenic Neoplasm, Survival Rate, Predictive value of tests, Human, Adult, medicine.medical_specialty, Lymphoma, B-Cell, Prognosi, Immunology, Disease-Free Survival, Predictive Value of Tests, Albumins, Internal medicine, Lactate dehydrogenase, Aged, Humans, Hydro-Lyases, Multivariate Analysis, Platelet Count, Splenic Neoplasms, Models, Theoretical, medicine, Hemoglobin, Splenic marginal zone lymphoma, Survival rate, business.industry, Albumin, Risk Factor, Cell Biology, medicine.disease, Surgery, chemistry, business
Abstract

The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100 000/μL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence on CSS in multivariate analysis were hemoglobin level less than 12 g/dL, LDH level greater than normal, and albumin level less than 3.5 g/dL. Using these 3 variables, we grouped patients into 3 prognostic categories: low-risk group (41%) with no adverse factors, intermediate-risk group (34%) with one adverse factor, and high-risk group (25%) with 2 or 3 adverse factors. The 5-year CSS rate was 88% for the low-risk group, 73% for the intermediate-risk group, and 50% for the high-risk group. The cause-specific mortality rate (x 1000 person-years) was 20 for the low-risk group, 47 for the intermediate-risk group, and 174 for the high-risk group. This latter group accounted for 54% of all lymphoma-related deaths. In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient. © 2006 by The American Society of Hematology.

Published
2006

40. 'Weekly regimen of cisplatin, epirubicin, 5-Fluorouracil and folinic acid with G-CSF is active in advanced gastroesophageal (GE) and gastric (G) cancer: a phase II study'

Author

PALMERI, Sergio, SCIUME', Carmelo, CAJOZZO, Massimo, RAIMONDI, Cristina, ABBADESSA, Vincenzo, MACALUSO, MC, VAGLICA, M, MANUGUERRA, G, DI CARLO, GP, SCHITTONE, L, BINI, G, IANNITTO, E, Cajozzo, M., PALMERI, S, MACALUSO, MC, SCIUME, C, CAJOZZO, M, VAGLICA, M, MANUGUERRA, G, DI CARLO, GP, SCHITTONE, L, BINI, G, RAIMONDI, C, IANNITTO, E, ABBADESSA, V, and Cajozzo, M

Published
2004

41. Presenting features and outcome of Splenic Marginal Zone Lymphoma with or without villous lymphocytes. A retrospective analysis in a Series of 145 Patients

Author

IANNITTO E, AMBROSETTI A, CALLEA V, STELITANO C, TRIPODO, Claudio, CALVARUSO G, MITRA ME, PATTI K, PIZZOLO G., FLORENA, Ada Maria, MINARDI, Viviana Maria, DE CANTIS, Stefano, ABBADESSA, Vincenzo, IANNITTO E, AMBROSETTI A, CALLEA V, STELITANO C, FLORENA A, TRIPODO C, MINARDI V, CALVARUSO G, MITRA ME, DE CANTIS S, PATTI K, ABBADESSA V, and PIZZOLO G

Published
2004

42. Splenic marginal zone lymphoma with or without villous lymphocytes

Author

IANNITTO E, AMBROSETTI A, COLOSIO M, CALVARUSO G, ENZA MITRA M, PIZZOLO G, MENESTRINA F, AMMATUNA, Emanuele, FLORENA, Ada Maria, TRIPODO, Claudio, MINARDI, Viviana Maria, FRANCO, Vito, IANNITTO E, AMBROSETTI A, AMMATUNA E, COLOSIO M, FLORENA AM, TRIPODO C, MINARDI V, CALVARUSO G, ENZA MITRA M, PIZZOLO G, MENESTRINA F, and FRANCO V

Subjects
Splenic marginal zone lymphoma
Abstract

The Integruppo Italiano Linfomi (IIL) carried out a study to assess the outcomes of splenic marginal zone lymphoma and to identify prognostic factors in 309 patients. The 5-year cause-specific survival (CSS) rate was 76%. In univariate analysis, the parameters predictive of shorter CSS were hemoglobin levels below 12 g/dL (P < .001), albumin levels below 3.5 g/dL (P = .001), International Prognostic Index (IPI) scores of 2 to 3 (P < .001), lactate dehydrogenase (LDH) levels above normal (P < .001), age older than 60 years (P = .01), platelet counts below 100,000/microL (P = .04), HbsAg-positivity (P = .01), and no splenectomy at diagnosis (P = .006). Values that maintained a negative influence on CSS in multivariate analysis were hemoglobin level less than 12 g/dL, LDH level greater than normal, and albumin level less than 3.5 g/dL. Using these 3 variables, we grouped patients into 3 prognostic categories: low-risk group (41%) with no adverse factors, intermediate-risk group (34%) with one adverse factor, and high-risk group (25%) with 2 or 3 adverse factors. The 5-year CSS rate was 88% for the low-risk group, 73% for the intermediate-risk group, and 50% for the high-risk group. The cause-specific mortality rate (x 1000 person-years) was 20 for the low-risk group, 47 for the intermediate-risk group, and 174 for the high-risk group. This latter group accounted for 54% of all lymphoma-related deaths. In conclusion, with the use of readily available factors, this prognostic index may be an effective tool for evaluating the need for treatment and the intensity of therapy in an individual patient.

Published
2004

43. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

Author

Gallamini, A., Stelitano, C., Calvi, R., Bellei, M., Mattei, D., Vitolo, U., Morabito, F., Martelli, M., Brusamolino, E., Iannitto, E., Zaja, F., Cortellazzo, S., Rigacci, L., Devizzi, L., Todeschini, G., Santini, G., Brugiatelli, M., Federico, M., Intergruppo Italiano Linfomi, Liberati, Anna Marina, Gallamini, A, Stelitano, C, Calvi, R, Bellei, M, Mattei, D, Vitolo, U, Morabito, F, Martelli, M, Brusamolino, E, Iannitto, E, Zaja, Francesco, Cortelazzo, S, Rigacci, L, Devizzi, L, Todeschini, G, Santini, G, Brugiatelli, M, and Federico, M.

Subjects
Male, medicine.medical_specialty, Multivariate analysis, Time Factors, B-CELL, Immunology, Peripheral T-cell lymphoma not otherwise specified, Antineoplastic Agents, Lymphoma, T-Cell, Biochemistry, Gastroenterology, NHL, REAL CLASSIFICATION, Peripheral T-cell lymphoma, new prognostic model, PROPOSAL, Internal medicine, medicine, Humans, Lupus Erythematosus, Systemic, NON-HODGKINS-LYMPHOMA, Stage (cooking), Neoplasm Staging, Retrospective Studies, RISK, Univariate analysis, Performance status, business.industry, Patient Selection, Cell Biology, Hematology, CHEMOTHERAPY, Middle Aged, medicine.disease, Prognosis, Combined Modality Therapy, Survival Analysis, Surgery, Lymphoma, Relative risk, Female, business, Follow-Up Studies, Stem Cell Transplantation
Abstract

To assess the prognosis of peripheral T-cell lymphoma unspecified, we retrospectively analyzed 385 cases fulfilling the criteria defined by the World Health Organization classification. Factors associated with a worse overall survival (OS) in a univariate analysis were age older than 60 years ( P = .0002), equal to or more than 2 extranodal sites ( P = .0002), lactic dehydrogenase (LDH) value at normal levels or above ( P < .0001), performance status (PS) equal to or more than 2 ( P ≤ .0001), stage III or higher ( P = .0001), and bone marrow involvement ( P = .0001). Multivariate analysis showed that age (relative risk, 1.732; 95% CI, 1.300-2.309; P < .0001), PS (relative risk, 1.719; 95% CI, 1.269-2.327, P < .0001), LDH level (relative risk, 1.905; 95% CI, 1.415-2.564; P < .0001), and bone marrow involvement (relative risk, 1.454; 95% CI, 1.045-2.023; P = .026) were factors independently predictive for survival. Using these 4 variables we constructed a new prognostic model that singled out 4 groups at different risk: group 1, no adverse factors, with 5-year and 10-year OS of 62.3% and 54.9%, respectively; group 2, one factor, with a 5-year and 10-year OS of 52.9% and 38.8%, respectively; group 3, 2 factors, with 5-year and 10-year OS of 32.9% and 18.0%, respectively; group 4, 3 or 4 factors, with a 5-year and 10-year OS of 18.3 and 12.6%, respectively ( P ≤ .0001; log-rank, 66.79).

Published
2004

44. Esmo Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL) follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

Author

Ghielmini, M, Vitolo, U, Kimby, E, Montoto, S, Walewski, J, Pfreundschuh, M, Federico, M, Hoskin, P, McNamara, C McNamara, Caligaris-Cappio, F, Stilgenbauer, S, Marcus, R, Trneny, M, Dreger, P, Montserrat, E, Dreyling, M, Agostinelli, C, Arcaini, L, Campo, E, Coiffier, B, Corradini, P, D'Amore, Francesco Annibale, Gallamini, A, Goulard, P, Geisler, CH, Gisselbrecht, C, Gomes da Silva, M, Gribben, J, Hermine, O, Iannitto, E, Kim, WS, Kluin-Nelemans, HC, Koch, P, Ladetto, M, Le Gouill, S, Lopez-Guillermo, A, Montalban, C, Raderer, M, Rodriguez, J, Salles, G, Bernard, C, Schmitz, N, Shpilberg, O, Thieblemont, C, Tilly, H, Tournilhac, O, Trümper, L, Wotherspoon, A, and Zucca, E

Published
2013

45. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Author

Alessandrino, Ep, Porta, Mg, Malcovati, L, Jackson, Ch, Pascutto, C, Bacigalupo, A, Teresa van Lint, M, Falda, M, Bernardi, M, Onida, F, Guidi, S, Iori, Ap, Cerretti, R, Marenco, P, Pioltelli, P, Angelucci, E, Oneto, R, Ripamonti, F, Rambaldi, A, Bosi, A, Cazzola, M, Gruppo Italiano Trapianto di Midollo Osseo Levis, A, Bandini, G, Casini, M, Rossi, G, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Van Lint MT, Corradini, P, Milani, R, Morra, E, Lambertenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scime, R, Iannitto, E, Musso, M, Locatelli, F, Zecca, M, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, Federico, Messina, G, Merli, F, Foa, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, B, Boccadoro, M, Fanin, R, Cerno, M, Bortolo, S, and Author information, Raimondi R.

Subjects
Oncology, Adolescent, Adult, Aged, Aged, 80 and over, Child, Cohort Studies, Female, Humans, Male, Markov Chains, Middle Aged, Myelodysplastic Syndromes, Risk, Survival Analysis, Time Factors, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation, Hematology, Homologous, medicine.medical_specialty, Allogeneic transplantation, medicine.medical_treatment, Hematopoietic stem cell transplantation, Natural history of disease, Internal medicine, medicine, 80 and over, Survival analysis, Transplantation, business.industry, Myelodysplastic syndromes, Original Articles, medicine.disease, Settore MED/15, Surgery, allogeneic transplantation, International Prognostic Scoring System, Risk assessment, business
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferior overall survival. To define the optimal timing of allogeneic HSCT, we carried out a decision analysis by studying 660 patients who received best supportive care and 449 subjects who underwent transplantation. Risk assessment was based on both the International Prognostic Scoring System (IPSS) and the World Health Organization classification-based Prognostic Scoring System (WPSS). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of allogeneic HSCT on survival. This model estimated life expectancy from diagnosis according to treatment policy at different risk stages. Relative to supportive care, estimated life expectancy increased when transplantation was delayed from the initial stages until progression to intermediate-1 IPSS-risk or to intermediate WPSS-risk stage, and then decreased for higher risks. Modeling decision analysis on WPSS versus IPSS allowed better estimation of the optimal timing of transplantation. These observations indicate that allogeneic HSCT offers optimal survival benefits when the procedure is performed before MDS patients progress to advanced disease stages. Am. J. Hematol. 88:581–588, 2013. © 2013 Wiley Periodicals, Inc.

Published
2013

46. Safety and Efficacy of Bendamustine With Or Without Rituximab In the Treatment of Heavily Pretreated Lymphoma Patients. A Multicenter Retrospective Study

Author

Rigacci, L., Iannitto, E., Puccini, B., Antognoli, G., D'Arco, A., Orciuolo, E., Cortelazzo, S., Gaidano, G., Freilone, R., Patti, C., Zaja, F., Gobbi, M., Musto, P., Zinzani, P. L., Storti, S., Isidori, A., Bongarzoni, V., Carpaneto, A., Renzo, N. D., Musso, M., Scalabrini, D. R., Santagostino, A., Stelitano, C., Cascavilla, N., Liberati, Anna Marina, Sancetta, R., and Bosi, A.

Published
2010

48. Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial

Author

Molica, Fabris, S., Cutrona, G., Matis, S., Pesce, E. A., Maura, F., Di Raimondo, G. Ciceri F., Musolino, C., Gobbi, M., Di Renzo, N., Romana Mauro, F., Cantaffa, R., Brugiatelli, M., Merli, F., Zupo, S., Mammi, C., Baldini, L., Angrilli, F., Quintana, G., Consoli, U., Iannitto, E., Di Tonno, P., Fragasso, A., Pellegrino, Musto, Cox, M. C., Festini, G., Callea, V., Sacchi, Stefano, Cortelezzi, A., Lambertenghi Deliliers, G., Foà, R., Federico, Massimo, Neri, A., Ferrarini, M., and Morabito, F.

Subjects
CLL
Published
2010

49. INCLUSION OF TOTAL BODY CT SCAN IN THE INITIAL WORK-UP OF CLL PATIENTS WITH EARLY-STAGE ON CLINICAL GROUNDS: PRELIMINARY RESULTS OF A PROSPECTIVE, MULTICENTER O-CLL1- GISL STUDY

Author

Gentile, M., Giovanna Cutrona, Fabris, S., Pesce, E., Di Raimondo, F., Di Renzo, N., Mauro, F. R., Cantaffa, R., Brugiatelli, M., Merli, F., Baldini, L., Quintana, G., Iannitto, E., Di Tonno, P., Fragasso, A., Molica, S., Callea, V., Sacchi, S., Federico, M., Neri, A., Ferrarini, M., and Morabito, F.

Subjects
nd
Published
2009

50. DIAGNOSTIC POTENTIAL OF CD38 COMBINED WITH ZAP70 EXPRESSION IN PREDICTING MUTATIONAL STATUS OF IMMUNOGLOBULIN HEAVY-CHAIN VARIABLE REGION IN CHRONIC LYMPHOCYTIC LEUKEMIA: PRELIMINARY RESULTS OF A PROSPECTIVE, MULTICENTER O-CLL1- GISL STUDY

Author

Gentile, M., Cutrona, G., Matis, S., Fabris, S., Pedemonte, S., Pesce, E. A., Di Raimondo, F., Musolino, C., Gobbi, M., Di Renzo, N., Mauro, Francesca Romana, Cantaffa, R., Brugiatelli, M., Merli, F., Zupo, S., Mammi, C., Baldini, L., Angrilli, F., Quintana, G., Consoli, U., Bertoldero, G., Iannitto, E., Di Tonno, P., Fragasso, A., Molica, S., Musto, P., Cox, M. C., Festini, G., Callea, V., Sacchi, S., Cortelezzi, A., Foa, Roberto, Federico, M., Neri, A., Ferrarini, M., and Morabito, F.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results